Skip to main content
← Back to Meds

Clinician handoff

Meds

Designed for a 60-second scan in primary care. Use this to explain why this theory fits, what would weaken it, and which tests are most worth discussing.

Why this still fits

My brain fog changed after a medication, dose change, or new combination. I want a medication review focused on cognitive effects before we assume this is just stress, aging, or depression.

What would weaken it

  • -No timeline linking the fog to a medication start, dose increase, timing shift, or stacking effect.
  • -The symptoms were clearly present before the medication picture changed and don't shift with dose timing.
  • -Sleep apnea, depression, thyroid disease, or another cause explains the pattern better than medication burden does.

Key points to communicate

  • •I want to review the full medication picture, not just the newest drug.
  • •Please separate sedation, anticholinergic burden, depletion effects, and rebound/timing effects from one another.
  • •If medication isn't the answer, I want to know which nearby causes still need real workup.

Bring this to the visit

  • •A full list of prescriptions, over-the-counter drugs, supplements, and PRN medications
  • •The exact time you take each medication and any recent dose changes
  • •A printed ACB score if you calculated one
  • •Any recent B12, ferritin, CBC, or magnesium-related labs if long-term PPIs or metformin are involved

Useful screening structure

  • -ACB score or Beers Criteria review when anticholinergic load is plausible
  • -Medication timeline showing when the fog started relative to the drug changes
  • -A clear note of what happens before a dose, after a dose, and when a drug wears off

Tests and measurements to discuss

Medication Review

What this helps clarify: Medication-related brain fog is often missed because nobody lays the full timeline out in one place.

Range context

Structured medication timeline + risk review

How to use the result

Ask whether a pharmacist-led medication therapy management review is available.

Anticholinergic Burden Review

What this helps clarify: Score >3 associated with cognitive decline

Range context

0 (none)

How to use the result

Save the result with date and symptoms from the same week.

Medication Depletion Panel

What this helps clarify: Some medications do not cause fog directly so much as they quietly deplete the nutrients the brain depends on.

Range context

Targeted nutrient depletion review

How to use the result

If a depletion is confirmed, ask whether you should replace it and whether the medication plan itself should change.

Vitamin B12

What this helps clarify: Patient-facing vitamin B12 explainer route, useful when a story or clinician uses plain language instead of the active-B12 variant.

Range context

Lab context

How to use the result

Save the result with date and symptoms from the same week.

Organic rule-outs still worth naming

  • •Sleep apnea if the fog is worst on waking and the sleep story is strong
  • •Depression or anxiety if the medication timeline is weak and the emotional symptoms lead the story
  • •Anemia, thyroid disease, or nutrient depletion if the medication explains part but not all of the picture

Questions to ask directly

  • •Which medications on my list are most likely to impair cognition?
  • •Is there a lower-burden alternative or safer timing strategy for the highest-risk drugs?
  • •Should we check B12, ferritin, CBC, magnesium context, or vitamin D because of my medication list?
  • •If a benzodiazepine or sedative is part of the problem, what would a safe taper look like?

Functional impact snapshot

  • -Driving confidence after sedating medications
  • -Work errors or slowed task switching after dose changes
  • -Whether the medication burden is causing you to avoid social or cognitive tasks

Escalate instead of self-managing if

  • •Sudden confusion, delirium, or severe sedation after a new medication
  • •Falls, blackout episodes, hallucinations, or breathing suppression
  • •Any abrupt self-directed stop of benzodiazepines, antidepressants, anticonvulsants, or antipsychotics

Peer-reviewed references

  1. 1. Coupland CAC et al. Anticholinergic Drug Exposure and the Risk of Dementia. JAMA Intern Med. 2019;179(8):1084-1093. PMID: 31233095 [DOI]
  2. 2. HTTPS://AGSJOURNALS.ONLINELIBRARY.WILEY.COM/DOI/10.1111/JGS.18372 [DOI]
  3. 3. Reeve E et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738-747. PMID: 24661192 [DOI]
  4. 4. O'Mahony D et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. PMID: 37256475 [DOI]
  5. 5. HTTPS://WWW.NICE.ORG.UK/GUIDANCE/NG5 [DOI]